Target
Kallikrein-1
Ligand
BDBM408775
Substrate
n/a
Meas. Tech.
Determination of the IC50 for KLK1
IC50
>40000±n/a nM
Citation
 Davie, RLEdwards, HJEvans, DMHodgson, STPethen, SJRooker, DP Pyrazole derivatives as plasma kallikrein inhibitors US Patent  US11180484 Publication Date 11/23/2021 
Target
Name:
Kallikrein-1
Synonyms:
KLK1 | KLK1_HUMAN | Kallikrein 1 | Kallikrein-1 | Kidney/pancreas/salivary gland kallikrein | Tissue kallikrein
Type:
Enzyme
Mol. Mass.:
28874.69
Organism:
Homo sapiens (Human)
Description:
P06870
Residue:
262
Sequence:
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS
  
Inhibitor
Name:
BDBM408775
Synonyms:
N-{[2-(difluoromethyl)-6-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4- [(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide | US10364238, Example 83 | US11001578, Example 83 | US11084809, Example 83 | US11198691, Example 83
Type:
Small organic molecule
Emp. Form.:
C28H27F3N4O4
Mol. Mass.:
540.5336
SMILES:
COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1C(F)F
Structure:
Search PDB for entries with ligand similarity: